Efficacy and safety of once-daily oral semaglutide 25 mg and 50 mg compared with 14 mg in adults with type 2 diabetes (PIONEER PLUS): a multicentre, randomised, phase 3b trial
Novo Nordisk A/S
Vanita R Aroda; Jens Aberle; Lars Bardtrum; Erik Christiansen; Filip K Knop; Sanaz Gabery; Sue D Pedersen; John B Buse